No Single Biosimilars Model Fits Europe, Says Samsung Bioepis’ Ko
Brazil Is Also A Key Part Of The Firm’s Strategy
Executive Summary
In the second part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out the firm’s strategy in Europe, as well as the importance of Brazil and China to its future plans.
You may also be interested in...
Samsung Bioepis Launches Trastuzumab In Brazil
Samsung Bioepis has launched its Ontruzant rival to Herceptin in Brazil, claiming the first biosimilar trastuzumab to be supplied to the country’s public health system for early and metastatic HER2-overexpressing breast cancer.
Samsung Bioepis Adds To Biogen Collaboration
Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.
Samsung Bioepis’ Ko Insists On Value Of Data
In the third and final part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko talks about the importance of real-world data in bolstering biosimilars, as well as outlining the firm’s future pipeline.